Bridget P Keenan

12PUBLICATIONS
70CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsSexualities
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 28, 2026
Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.

|Aug 14, 2026
A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer.

|May 07, 2026
Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations.

|Oct 08, 2025
Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases.

Bridget P Keenan, Guilin Qiao, Nicholas Kunda

|Feb 05, 2025
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers.

Andrew H Ko, Joseph Chao, Marcus S Noel

|Jan 05, 2024
Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer.

Maira Soto, Erin L Filbert, Hai Yang

Pageof 2

Frequent Collaborators

6 joint publications

Lawrence Fong

3 joint publications

Andrew Ko

2 joint publications

Li Zhang

2 joint publications

Frank J Hsu